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Background: Clinical Practice Guidelines recommend using peripheral blood pulse measuring as a screening test
for Atrial Fibrillation. However, there is no adequate evidence supporting the efficacy of such procedure in primary
care clinical practice. This paper describes a study protocol designed to verify whether early opportunistic screening
for Atrial Fibrillation by measuring blood pulse is more effective than regular practice in subjects aged 65 years
attending primary care centers.
Methods/design: An cluster-randomized controlled trial conducted in Primary Care Centers of the Spanish National
Health Service. A total of 269 physicians and nurses will be allocated to one of the two arms of the trial by stratified
randomization with a 3:2 ratio (three practitioners will be assigned to the Control Group for every two practitioners
assigned to the Experimental Group). As many as 12 870 patients aged 65 years or older and meeting eligibility
criteria will be recruited (8 580 will be allocated to the Experimental Group and 4 290 to the Control Group).
Randomization and allocation to trial groups will be carried out by a central computer system. The Experimental
Group practitioners will conduct an opportunistic case finding for patients with Atrial Fibrillation, while the Control
Group practitioners will follow the regular guidelines. The first step will be finding new Atrial Fibrillation cases. A
descriptive inferential analysis will be performed (bivariate and multivariate by multilevel logistic regression analysis).
Discussion: If our hypothesis is confirmed, we expect Primary Care professionals to take a more proactive approach
and adopt a new protocol when a patient meeting the established screening criteria is identified. Finally, we expect
this measure to be incorporated into Clinical Practice Guidelines.
Trial registration: The study is registered as NCT01291953 (ClinicalTrials.gob)
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Atrial fibrillation (AF) is defined as a cardiac arrhythmia
involving irregular atrial activation, uncoordinated atrial
systole and ineffective ventricular filling. ECG shows no P
wave but displays fast fibrillation waves different in form,
size and rhythm that lead to an irregular ventricular re-
sponse. Echocardiogram shows no mitral A wave valvular
movement [1]. AF is the most frequent arrhythmia in
clinical practice and a growing challenge to public health
due to population aging. The estimated prevalence of AF
is 0.4-1% in the general population and increases with age
up to 5-6% in the population aged > 65 years, and 8% in
subjects aged 80 years or older [2,3]. Similarly, while the
incidence of AF is < 0.1% per year in subjects aged < 40
years, it increases to above 1.5% per year in women and
2% in men aged > 80 years [4]. The incidence of AF was
expected to increase 5-fold by the year 2010 [5-8].
According to the Framingham Heart Study, lifetime risk
for AF is 1 in 4 in men and women aged 40 years or older.
Lifetime risks remain greater even in absence of congest-
ive heart failure or myocardial infarction (1 in 6) [9]. AF
is one of the fastest-growing cardiovascular epidemics of
the 21st century, as it is one the major causes of morbidity
and mortality, and it increases death risk, congestive heart
failure and the risk for embolisms –including strokes
[6,10-12]. One in every six strokes occur in subjects with
AF [13,14], and the increased risk for ictus depends on
the number of additional risk factors. In addition, the
quality of life of these patients is severely impaired,
mainly due to their inability to perform daily activities as
a result of the risk of exacerbation of symptoms [15].
Over the last 20 years, admissions for AF have increased
by 66% as a result of population aging, the increasing
prevalence of chronic heart diseases, the more frequent
diagnosis by ambulatory control mechanisms, and other
factors [16].
A third of patients have asymptomatic AF. AF evolves
from rare asymptomatic episodes to longer and more fre-
quent strokes until it becomes permanent. Occasionally,
AF is detected after an ECG performed during a
hospitalization without a principal discharge diagnosis of
AF [1]. The treatment of these patients represents a chal-
lenge continuously revised by experts [17]. The risk for
cardioembolic processes in these patients significantly
decreases with preventive treatment with oral anticoagu-
lant drugs, which reduce relative risk by 68% and relative
mortality by 2.5%, as compared with placebo [1].
Before recommending a screening test, a set of epide-
miologic requirements should be met. The goal is to
achieve a significant improvement in the prognosis of AF,
since the decrease in the associated morbidity and mor-
tality rates is greater when screening is performed. Early
screening for AF might be highly beneficial for patients.
The systematical population screening –especially in theelderly, as they are at a greater risk for AF and its compli-
cations–would be of great interest. The AF AWARE
(Atrial Fibrillation Awareness And Risk Education) study,
performed in 2009 in 11 countries with 810 cardiologists
and 825 patients with AF concluded that early AF screen-
ing and treatment may help reduce severe AF-related
risks [18]. Some studies have assessed the role of screen-
ing for AF, although it is more frequently detected and
diagnosed when it becomes symptomatic [19-24].
Fitzmaurice et al [25] studied the cost-effectiveness of sys-
tematic screening versus the performance of ECG, and
they concluded that blood pulse measuring is the best
practice in cost-effectiveness terms; finally, they suggested
the need for further studies assessing the efficacy of early
screening for AF versus regular clinical practice. The
practice of screening for AF in the elderly meets most of
the criteria established by Wilson & Jungner to evaluate
its implementation [26]: it is a usual and comprehensive
process; it can be detected by simple procedures (blood
pulse measuring is inexpensive, simple and harmless);
diagnosis of AF can be confirmed by a simple and highly
sensitive and specific test (ECC); screening for AF is free
of iatrogenic effects, and the risk for complications or side
effects as stroke can be significantly reduced with the
available treatments. Two screening procedures have been
proposed: opportunistic screening (performing screening
when the practitioner sees a patient for any reason), or
systematic (encouraging the patient to undergo a screen-
ing). There is evidence that the opportunistic option is the
most appropriate [27].
The most recent Clinical Practice Guidelines recom-
mend measuring blood pulse to test for suspected AF,
and performing ECG to confirm a diagnosis of AF [28].
However, there is not adequate evidence supporting this
recommendation, especially in the context of Primary
Care.
Research objectives
The three main aims of this study are:
– To establish the percentage of patients with AF
identified “de novo” by radial pulse assessment as
compared to those discovered by regular clinical
practice.
– To know the amount of asymptomatic AF patients,
and the symptoms and clinical signs showed by
symptomatic AF patients.
– To identify the different AF typologies following
expert panels’ classifications.
Complementary objectives are:
– To know the socio-demographics of the population
with AF.
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condition (comorbidity and risk factors).
– To know the previous treatment followed by these
patients.
Methods/design
Design of the study
A open, cluster, multicenter, two-arm, individual random-
ization, controlled trial of the efficacy of performing
opportunistic screening versus regular clinical practice
(Figure 1).
Setting
Spanish National Health system. Primary Care physi-
cians and nurses working in health centers in Barcelona,
Córdoba and Badajoz. The study will have a duration of
12 months; fieldwork will have a duration of 5 months.
Participants
The selection criteria were:
* Eligibility Criteria:
– Men and women aged ≥ 65 years attending their
health center for any reason.TARGET POPULATION
STUDY POPULATION
269 Family physicians/nurses 
(12 870 patients) 
Cluster randomization (2:3 ratio) stratified
center and profession
EXPERIMENTAL GROUP: 108 professionals CONTR
Opportunistic Screening (8 580 patients) Regula
Arterial Pulse Measuring 





Figure 1 Design of DOFA-AP study.* Exclusion Criteria:
– Previous AF diagnosis (prevalent cases): we will
measure the characteristics of patients previously
diagnosed with AF and process the data obtained
as existing cases, for statistic purposes.
Sample size
The primary endpoint will be the percentage of AF
cases; sample size estimation was performed according
to the results obtained by Fitzmaurice DA [25] in its trial
of effectiveness, using EPIDAT 3.1 software [29] and
within the following criteria:
– Risk in exposed patients: 1.63%; risk in non-exposed:
1.012%, expected relative risk: 1.62%.
– Controls –CG– per case –EG–: 0.5 (1:2 ratio). With
this ratio, we intend to optimize and make the study
feasible, as it will be more difficult to identify and
recruit controls.
– Confidence level: 95.0%; accuracy: 80%; the resulting
sample size is 7 722 subjects for the EG, and 3 861
subjects for the CG. As we estimated a non-
response rate of 10%, we adjusted the formula
Nf= Ni [1/(1-R)]=7 722 [1/(1-0,10)]= 8 580 (GE) by 
OL GROUP: 161 professionals
r Intervention (4 290 patients)
rterial Pulse Measuring 
and ECG if +
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Consequently, the total N= 8 580 + 4 290=12 870
subjects. As this is a cluster design study and
according to the study referenced above [25], at least
100 health professionals should recruit at least 12
000 patients. Since the probability of finding patients
meeting the eligibility criteria is much lower for the
CG than for the EG, stratified randomization will be
used to assign at least 200 primary care health
professionals to the two groups, with a 2:3 ratio. In
other words, there will be three CG health
practitioners for every two EG practitioners.
Patient selection will be performed by consecutive
sampling.
Randomisation
Researchers will be assigned to one of the study groups
by stratified randomization based on the center and the
type of health professional (GP/nurse) using EPIDAT 3.1
software [29].
Interventions and comparative analysis
- EG: All patients seen by the health professionals
involved in the present study will undergo active screen-
ing for AF, regardless of the reason of their visit. There-
fore, the health professional will adopt a “proactive”
attitude of opportunistic case finding, either because the
professional identifies “silent” AF cases, or because
screening for AF was performed, while the patient pre-
sented AF-associated symptoms, signs or pathologies.
-CG: Any patient presenting AF-accompanying symp-
toms (dyspnea, chest pain, palpitations or dizziness) or
AF-induced sequels (stroke, transient ischemic attacks,
peripheral embolism, heart failure or other associated
health disorders) will be eligible. Once the practitioner
identifies any of these symptoms, they will perform a
screening for AF by measuring the patient’s blood pulse.
Measurement Instruments and action program
1. A Data Collection Form (DCF) and a Procedure
Manual including a Clinical Protocol based on an
updated Practice Guideline will be designed [30].
2. A pilot study has already been conducted on a
sample of 20 randomized patients in five health
centers located in Barcelona and Córdoba, where five
GP and five nurses participated. The target
population was willing to undergo the test. The data
collected by the DCF allowed practitioners to identify
two cases of undiagnosed asymptomatic AF.
3. Communication Plan and Recruitment of Health
Professionals: the project managers of the study were
in charge of the dissemination of the study; inaddition, a presentation of the study was performed
in different health centers in Barcelona, Córdoba and
Badajoz. A total of 269 health professionals at 28
health centers agreed to participate in the study (162
GPs and 107 nurses).
4. Training Plan. A presentation will be given to
familiarize the participating practitioners with the
study protocol. All participants will take an on-line
course on how to approach patients with AF (http://
www.semfyc.es/pfw_files/cma/Agenda/
Sesiones_multimedia/Documentos/
Diptico_referentes_fa.pdf ). On the first stage, we
intend to designate a practitioner as the expert in FA.
The practitioner selected will take an online course
to acquire the abilities and skills necessary to be able
to give a training session to his/her partners.
Measurements and Variables
The variables measured are shown in Table 1.
-Statistical Analysis
Statistical analysis will be performed with the statistics
analysis software EPIDAT 3.1 [29], SPSS [33], and
WLwiN 2.02 [34]. It will include:
a. Descriptive Analysis: characteristics of the population
under study (sociodemographic variables): central
tendency, dispersion and position measures for
quantitative variables; and tabulation and calculation
of relative frequencies for qualitative variables. A
calculation of major estimators with their
corresponding 95% confidence intervals (CI95%) will
be performed.
b. Bivariate Analysis: We will examine basal
comparability between the two groups using the chi-
square test or Fisher’s test (proportion comparison
test), or by Student’s t-test (mean comparison test
after testing normal distribution). Then, the AF
dependent variable will be examined and crossed
with the sociodemographic variables and other
independent or prognostic variables of interest. On
such purpose, we will use Pearson’s chi square tests
or Fisher’s test (qualitative variables), and Student’s t-
test or ANOVA (quantitative variables). All contrasts
will be bilateral (p < 0.05).
c. Analysis of the relationship between the type of
intervention and the primary variable of the study
(AF): contingency tables, square chi test, relative risk
estimation), attributable risk and number of subjects
to be treated, with their respective CI95%.
d. Multivariate Analysis: A multi-level logistic
regression or multiple logistic regression will be
performed to compare effects of the strategy on both
groups (Odds Ratio) adjusting the model for
Table 1 Variables of the Study
Variables Definition Measure scale
Independet
-Study Groups EG: Opportunistic detection of AF Dichotomous Qualitative
CG: regular approach
-Practitioner Physician vs. Nurse Dichotomous Qualitative
-Sociodemographic:
Age ≥ 65 years Quantitative Discrete
Sex Man/woman Dichotomous Qualitative
Marital Status bachelor, married, widow/er, divorced Qualitative Polytomous
Residence Urban (≥ 10.000 population)/Rural (<10.000 population) Dichotomous Qualitative
-Clinical and Functional Assessment:
Symptoms and Signs Asymptomatic, Palpitations, Chest Pain, dispnoea, fatigue,
diziness, embolism complications or exacerbation of heart
failure, weight loss, diarrhea.
Polytomous Qualitative
Conditions (comorbidity) and associated health disorders High blood pressure, heart disease, mitral stenosis, mitral
regurgitation, hypertrophic cardiomyopathy, pericarditis,
congenital heart disease, previous cardiac surgery, lung
diseases (pneumonia, lung cancer, pulmonary embolism,
sarcoidosis), alcohol abuse, hyperthyroidism, bone and joint
disorders, neurological, hearing, vision, feet, psychic, digestive,
urinary, sleep disorders, other.
Polytomous Qualitative
To classify chronic disorders we will use the electronic
version of the Second International Clasiffication of Primary
Care (ICPC-2-E) [31]
Family History of AF Parents, siblings, children Polytomous Qualitative
Drug Consumption for Cardiovascular Disease Name of the drug: The Anatomical Therapeutic Classification
(AT) developed by the European Pharmaceutical Market
Research Association (EPhMRA) [32]
Polytomous Qualitative
Number of Drugs Drugs currently consumed Discrete
Quantitative
Dependent:
Peripheral Blood Pulse Radial pulse measuring according to the protocol:
Regular/Irregular
Dichotomous Qualitative
Atrial Fibrillation ECG according to the clinical protocol Dichotomous Qualitative
Treatment Pharmacological (Antiarrhythmic / Anticoagulation)/
Non-pharmacological (Cardioversion)
Polytomous Qualitative
Pérula-de-Torres et al. BMC Family Practice 2012, 13:106 Page 5 of 7
http://www.biomedcentral.com/1471-2296/13/106potential prognostic and / or confounding candidate
variables. When multiple logistic regression is used,
these variables will be introduced by the “Enter”
technique. Significance will be > 0.10 according to
Wald’s test.
Protection against bias
The study is open, so the intervention cannot be
masked. Therefore, both, patients and practitioners will
know who is involved in the intervention, and this might
condition their response (Hawthorne effect), especially
in the control group. Just the fact that the participants
are identified and express their wish to participate in the
study, and since they are subject to more intensive
monitoring than usual, might make them more willing
to follow medical advice.Information bias can occur through errors in FA iden-
tification on the ECG due the practitioner’s inadequate
skills. Practitioners will previously take a training course.
The degree of interobserver reliability and agreement on
blood pulse measuring will be examined.
Another bias might occur in the selection of patients,
as one of the groups might include more patients diag-
nosed with AF before the study period. Should this occur
in the control group, the beneficial effect of screening




This study will assess the effectiveness of early detection
of AF. If our hypothesis is confirmed, we expect Primary
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and adopt a new protocol when a patient meeting the
established screening criteria is identified. Finally, we
expect this measure to be incorporated into Clinical
Practice Guidelines.Ethical considerations
The research project has been approved by the Ethics
Committees of the Hospital de Mataró (Barcelona) and
the Hospital Reina Sof ía (Córdoba). Informed consent
will be previously obtained from all participants. This
project will be conducted under the provisions of the
Declaration of Helsinki, the European Council agreement
on Human Rights and Biomedicine, and the UNESCO
Universal Declaration.
The design and development of this study will be per-
formed within Best Practice and Confidentiality norms
(protection of personal data) and other national and
international laws in force regulating health research.
This trial is registered in ClinicalTrials.gob (NCT01291953).Organization and logistics of the study
Systematic tracking of the fieldwork will be performed
by a technical instructor, a monthly phone conversation
with every practitioner, and collecting recruitment and
DCF data. Subsequently, a case-based reasoning will be
submitted to each practitioner.
Coordination meetings with the project management
team will be held via Second Life (http://secondlife.com/)
at least once every two months over the study period.
Additional file
Additional file 1: Appendix Participants in the Collaborative Group
of the DOFA-AP (Acronym of “Detección Oportunista de Fibrilación
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